FloWatch: A Medical Device to Protect Newborns with Congenital Heart Defects
EspeRare is reviving and relaunching the FloWatch-PAB device, a therapeutic device that has medically proven abilities to protect the heart and lungs of newborn babies with severe cardiac defects while they wait to undergo a surgical operation to repair their hearts.
The FloWatch technology was developed at EPFL (Switzerland) and combines a micro-engine inspired from Swiss watchmakers with a telemetric control system developed at ETH Zurich (Switzerland). EspeRare is relaunching the quality, regulatory and manufacturing processes in order to secure the European market authorization in 2017.
Over the next 2 to 3 years, EspeRare wishes to produce and distribute around 200 units. Fulfilling EspeRare’s not-for-profit goals, part of the FloWatch devices produced will be distributed in Africa and in Asia. In these regions, only a small number of newborns have access to the heart repair surgery so that protecting these babies’ hearts with FloWatch is even more pressing and can prove to be vitally important.